Support Line: 0800 002 9002
General Enquiries: 01223 870008

Tivozanib (Fotivda)

Tivozanib (Fotivda) is indicated for ‘the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC’.

Application- Tablet
Availability: UK